Shares of GSK plc (LON:GSK – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is GBX 1,842.50 ($23.89).
Several analysts have issued reports on GSK shares. Berenberg Bank restated a “buy” rating and issued a GBX 1,820 ($23.60) target price on shares of GSK in a research note on Tuesday, September 10th. Shore Capital reiterated a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,850 ($23.99) price target on shares of GSK in a research note on Tuesday, September 3rd.
View Our Latest Analysis on GSK
Insider Buying and Selling
GSK Trading Up 1.9 %
Shares of LON GSK opened at GBX 1,419.50 ($18.41) on Thursday. The stock has a market cap of £57.92 billion, a P/E ratio of 1,256.19, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. GSK has a 52-week low of GBX 1,371.40 ($17.78) and a 52-week high of GBX 1,823.50 ($23.65). The firm has a 50 day moving average price of GBX 1,541.78 and a two-hundred day moving average price of GBX 1,593.52.
GSK Dividend Announcement
The company also recently disclosed a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be given a GBX 15 ($0.19) dividend. The ex-dividend date is Thursday, November 14th. This represents a dividend yield of 1.03%. GSK’s dividend payout ratio (DPR) is currently 5,309.73%.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Recommended Stories
- Five stocks we like better than GSK
- Market Cap Calculator: How to Calculate Market Cap
- Battle of the Retailers: Who Comes Out on Top?
- What is an Earnings Surprise?
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Profitably Trade Stocks at 52-Week Highs
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.